MX2021011044A - Potassium-binding agents for use in hemodialysis patients. - Google Patents
Potassium-binding agents for use in hemodialysis patients.Info
- Publication number
- MX2021011044A MX2021011044A MX2021011044A MX2021011044A MX2021011044A MX 2021011044 A MX2021011044 A MX 2021011044A MX 2021011044 A MX2021011044 A MX 2021011044A MX 2021011044 A MX2021011044 A MX 2021011044A MX 2021011044 A MX2021011044 A MX 2021011044A
- Authority
- MX
- Mexico
- Prior art keywords
- potassium
- binding agents
- hemodialysis patients
- relapse
- formulated
- Prior art date
Links
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 title abstract 2
- 239000011230 binding agent Substances 0.000 title abstract 2
- 238000001631 haemodialysis Methods 0.000 title abstract 2
- 230000000322 hemodialysis Effects 0.000 title abstract 2
- 229910052700 potassium Inorganic materials 0.000 title abstract 2
- 239000011591 potassium Substances 0.000 title abstract 2
- 208000002682 Hyperkalemia Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910001414 potassium ion Inorganic materials 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to the use of potassium-binding agents that are formulated to remove toxins, e.g., potassium ions, from the gastrointestinal tract at an elevated rate, without causing undesirable side effects, in hemodialysis patients. The compositions exhibit desired characteristics for the long term administration to treat or prevent the relapse or occurrence of certain conditions, for example hyperkalemia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962817817P | 2019-03-13 | 2019-03-13 | |
| PCT/EP2020/056595 WO2020182927A1 (en) | 2019-03-13 | 2020-03-12 | Potassium-binding agents for use in hemodialysis patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021011044A true MX2021011044A (en) | 2021-10-13 |
Family
ID=69810853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011044A MX2021011044A (en) | 2019-03-13 | 2020-03-12 | Potassium-binding agents for use in hemodialysis patients. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220218738A1 (en) |
| EP (1) | EP3937953A1 (en) |
| JP (1) | JP2022524454A (en) |
| KR (1) | KR20210137154A (en) |
| CN (2) | CN117137944A (en) |
| AU (1) | AU2020235911A1 (en) |
| BR (1) | BR112021017791A2 (en) |
| CA (1) | CA3132563A1 (en) |
| EA (1) | EA202192425A1 (en) |
| IL (1) | IL286029A (en) |
| MA (1) | MA55287A (en) |
| MX (1) | MX2021011044A (en) |
| SG (1) | SG11202109834XA (en) |
| WO (1) | WO2020182927A1 (en) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5891417A (en) | 1997-04-08 | 1999-04-06 | Uop Llc | Zirconium silicate and zirconium germanate molecular sieves and process using the same |
| US5888472A (en) | 1997-04-08 | 1999-03-30 | Uop Llc | Zirconium silicate molecular sieves and process using the same |
| US6332985B1 (en) | 1999-03-29 | 2001-12-25 | Uop Llc | Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions |
| US6099737A (en) | 1999-03-29 | 2000-08-08 | Uop Llc | Process for removing toxins from blood using zirconium metallate or titanium metallate compositions |
| AU2002242103A1 (en) | 2001-02-06 | 2002-08-19 | Ash Medical Systems, Inc. | Monovalent-selective cation exchangers as oral sorbent therapy |
| US6579460B1 (en) | 2001-03-13 | 2003-06-17 | Uop Llc | Process and composition for removing toxins from bodily fluids |
| US6814871B1 (en) | 2001-07-13 | 2004-11-09 | Uop Llc | Process for removing pollutants from aqueous streams |
| GB2475657B (en) * | 2008-08-22 | 2013-05-29 | Relypsa Inc | Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia |
| TR201901002T4 (en) | 2011-02-11 | 2019-02-21 | Zs Pharma Inc | Use of zirconium silicate for the treatment of hyperkalaemia. |
| JP6423795B2 (en) | 2012-10-22 | 2018-11-14 | ズィーエス・ファーマ，インコーポレーテッド | Microporous zirconium silicate for the treatment of hyperkalemia |
| EP4378577A2 (en) * | 2013-11-08 | 2024-06-05 | ZS Pharma, Inc | Microporous zirconium silicate for the treatment of hyperkalemia |
| WO2015070015A1 (en) * | 2013-11-08 | 2015-05-14 | ZS Pharma, Inc. | Microporous zirconium silicate for the treatment of hyperkalemia |
| US9592253B1 (en) | 2015-10-14 | 2017-03-14 | ZS Pharma, Inc. | Extended use zirconium silicate compositions and methods of use thereof |
-
2020
- 2020-03-12 BR BR112021017791A patent/BR112021017791A2/en unknown
- 2020-03-12 CN CN202311287942.8A patent/CN117137944A/en active Pending
- 2020-03-12 MX MX2021011044A patent/MX2021011044A/en unknown
- 2020-03-12 JP JP2021554976A patent/JP2022524454A/en active Pending
- 2020-03-12 CA CA3132563A patent/CA3132563A1/en active Pending
- 2020-03-12 EP EP20711138.6A patent/EP3937953A1/en not_active Withdrawn
- 2020-03-12 WO PCT/EP2020/056595 patent/WO2020182927A1/en unknown
- 2020-03-12 SG SG11202109834X patent/SG11202109834XA/en unknown
- 2020-03-12 KR KR1020217032459A patent/KR20210137154A/en unknown
- 2020-03-12 EA EA202192425A patent/EA202192425A1/en unknown
- 2020-03-12 AU AU2020235911A patent/AU2020235911A1/en not_active Abandoned
- 2020-03-12 MA MA055287A patent/MA55287A/en unknown
- 2020-03-12 CN CN202080020401.7A patent/CN113557024A/en active Pending
- 2020-03-12 US US17/593,127 patent/US20220218738A1/en active Pending
-
2021
- 2021-09-01 IL IL286029A patent/IL286029A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117137944A (en) | 2023-12-01 |
| SG11202109834XA (en) | 2021-10-28 |
| BR112021017791A2 (en) | 2022-02-01 |
| CN113557024A (en) | 2021-10-26 |
| IL286029A (en) | 2021-10-31 |
| EP3937953A1 (en) | 2022-01-19 |
| WO2020182927A1 (en) | 2020-09-17 |
| KR20210137154A (en) | 2021-11-17 |
| MA55287A (en) | 2022-01-19 |
| CA3132563A1 (en) | 2020-09-17 |
| JP2022524454A (en) | 2022-05-02 |
| US20220218738A1 (en) | 2022-07-14 |
| EA202192425A1 (en) | 2021-12-06 |
| AU2020235911A1 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023012245A (en) | Compounds, compositions and methods of treating cancer. | |
| MA43335A (en) | TRANSTHYRETINE (TTR) RNA COMPOSITIONS AND METHODS FOR USING THEM FOR THE TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH TTR | |
| MX2021005350A (en) | Pyridazinone compounds and uses thereof. | |
| MX2017012738A (en) | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer. | |
| EA201891268A1 (en) | COMPOUNDS WHICH CAN BE USED AS KINASE INHIBITORS | |
| AU2017228405A8 (en) | Small molecule IRE1-alpha inhibitors | |
| MX2022000453A (en) | Compounds useful to treat influenza virus infections. | |
| MX2021005348A (en) | Pyridazinone compounds and uses thereof. | |
| MX2015008889A (en) | Method for treating cancer based on mutation status of k-ras. | |
| MX2018005041A (en) | Compounds for treating amyotrophic lateral sclerosis. | |
| MX2019002438A (en) | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections. | |
| CR20190519A (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| MX2016005940A (en) | Microporous zirconium silicate for the treatment of hyperkalemia. | |
| EP4342473A3 (en) | Compounds useful in hiv therapy | |
| MX2017015923A (en) | Ido inhibitors. | |
| MA34968B1 (en) | ASYMMETRIC UREA AND MEDICAL USES THEREOF | |
| MX2009008495A (en) | Novel nucleoside analogs for treatment of viral infections. | |
| CR20210460A (en) | Compounds useful in hiv therapy | |
| MX2023002233A (en) | Phospholipid compounds and uses thereof. | |
| MX2021002305A (en) | Treating liver disorders. | |
| MX2018005045A (en) | FACTOR XIa INHIBITORS. | |
| MX2020012800A (en) | Cannabinoids and uses thereof. | |
| EP4275761A3 (en) | Alkaline phosphatase agents for treatment of radiation disorders | |
| MA43052B1 (en) | Human Plasma Kallikrein Inhibitors | |
| MX2017009445A (en) | Factor xia inhibitors. |